# Advisor Review - Advisor 2/3

**Role:** Academic advisor checking for fatal errors
**Model:** gpt-5.2-2025-12-11
**Paper:** paper.pdf
**Reasoning effort:** high
**Timestamp:** 2026-01-28T19:18:25.860755
**Response ID:** resp_09f8f06f98d8b31d00697a521e41e88196a6f302d0217c4d63
**Tokens:** 9156 in / 9350 out
**Response SHA256:** 5ef265b2a276e580

---

## 1) DATA–DESIGN ALIGNMENT (CRITICAL)

- **Treatment timing vs. data coverage:** Cohort years shown (Figure 2: 2011–2019) are **within** the stated ACS window **2010–2022**. No treated cohort occurs after 2022.  
  ⇒ **No fatal misalignment** (max cohort year ≤ max data year).

- **Post-treatment observations:** For the latest cohorts (e.g., 2019), the dataset still contains multiple post years (2019–2022). Early cohorts have long post periods.  
  ⇒ **No cohort lacks post-treatment data**.

- **Treatment definition consistency:** The paper consistently defines the cohort as the **first full calendar year** with MW > $7.25 and states that **partial-exposure years are excluded** for mid-year effective dates. The reported state-year counts (Table 1: 260 control + 226 treated = 486 total) are consistent with dropping a small number of partial years (38 states × 13 years = 494 potential; 494 − 486 = 8 dropped).  
  ⇒ **No internal contradiction that breaks the design**.

## 2) REGRESSION SANITY (CRITICAL)

Checked all reported regression tables:

- **Table 2:** Coefficients and SEs are in plausible ranges for employment rates (0–1 outcome). No extreme SEs, no obviously broken outputs, no impossible values.
- **Table 3:** Same—magnitudes and SEs are plausible; nothing mechanically inconsistent.

⇒ **No fatal regression sanity violations**.

## 3) COMPLETENESS (CRITICAL)

- No placeholders (“TBD”, “NA”, etc.) detected in the provided tables/appendix.
- Regression tables report **standard errors** and **sample sizes (Observations, States)** (Table 2; Table 3 reports N and states).
- Figures and tables cited in the provided excerpt (Figures 1–3, Tables 1–3, appendices) appear to exist in the draft text you supplied.

⇒ **No fatal completeness problems**.

## 4) INTERNAL CONSISTENCY (CRITICAL)

- Main numerical claims match the tables: e.g., the “1.2 percentage point” effect corresponds to Table 2, Col. (1) ATT = −0.012; “concentrated among 65–74” corresponds to Table 3 Panel A (−0.015); placebo is near zero in Table 2 Col. (4).
- Sample period statements (2010–2022) align with the observation counts and the cohort distribution shown.

⇒ **No fatal internal inconsistencies found**.

ADVISOR VERDICT: PASS